Clinical characteristics of the patients with t-MDS/t-AML in the 2 study groups
| . | University of Chicago patients, no. . | United Kingdom patients, no. . |
|---|---|---|
| Patients with secondary disease | 80 | 91 |
| Sex, M/F | 37/43 | 38/53 |
| Primary cancer diagnosis | 78 | 51 |
| Hematologic malignancies | 40 | 19 |
| Leukemia | 9 | 4 |
| Hodgkin disease | 14 | 11 |
| Non-Hodgkin lymphoma | 16 | 4 |
| Myeloma | 1 | 0 |
| Solid tumors | 38 | 32 |
| Breast cancer | 17 | 15 |
| Other | 21* | 17† |
| Other disease | 2‡ | 6§ |
| Secondary leukemia | ||
| Acute myeloid | 62 | 91 |
| Myelodysplastic syndrome | 18 | 0 |
| Treatment modality | ||
| Radiation therapy only | 11 | 40 |
| Chemotherapy only | 32 | 32 |
| Combined modality therapy | 37 | 19 |
| Cytogenetic subtype | ||
| Chromosome 5, 7, or both | 51 | 22 |
| Translocation/inversion | 9 | 12 |
| Other | 10 | 13 |
| Normal | 8 | 24 |
| No information | 2 | 20 |
| Mean age at t-MDS/t-AML, y (SD) | 57.5 (15.8) | 55.3 (13.4) |
| . | University of Chicago patients, no. . | United Kingdom patients, no. . |
|---|---|---|
| Patients with secondary disease | 80 | 91 |
| Sex, M/F | 37/43 | 38/53 |
| Primary cancer diagnosis | 78 | 51 |
| Hematologic malignancies | 40 | 19 |
| Leukemia | 9 | 4 |
| Hodgkin disease | 14 | 11 |
| Non-Hodgkin lymphoma | 16 | 4 |
| Myeloma | 1 | 0 |
| Solid tumors | 38 | 32 |
| Breast cancer | 17 | 15 |
| Other | 21* | 17† |
| Other disease | 2‡ | 6§ |
| Secondary leukemia | ||
| Acute myeloid | 62 | 91 |
| Myelodysplastic syndrome | 18 | 0 |
| Treatment modality | ||
| Radiation therapy only | 11 | 40 |
| Chemotherapy only | 32 | 32 |
| Combined modality therapy | 37 | 19 |
| Cytogenetic subtype | ||
| Chromosome 5, 7, or both | 51 | 22 |
| Translocation/inversion | 9 | 12 |
| Other | 10 | 13 |
| Normal | 8 | 24 |
| No information | 2 | 20 |
| Mean age at t-MDS/t-AML, y (SD) | 57.5 (15.8) | 55.3 (13.4) |
Includes cancers of the cervix (2), esophagus, head and neck, lung, ovaries (4), prostate (3), rectum, stomach, testis, thyroid (2), and vulva; astrocytoma; a sarcoma; and a primary site unknown.
Includes cancers of the bladder, cervix (2), colon, lung (2), prostate (2), testis, and uterus (4); basal cell carcinoma; malignant histiocytosis (2); and osteosarcoma.
Includes the diagnosis of Crohn disease (2).
Includes diagnoses of goiter, rheumatoid arthritis, sarcoidosis, systemic vasculitis, retinal vasculitis, and tuberculosis.